
US Patent No: 4,474,893
Number of patents in Portfolio can not be more than 2000
Recombinant monoclonal antibodies
Stats
-
Oct 2, 1984
Issued date -
Jul 1, 1981
filing date -
06/279,248
serial no -
Expired
status

Importance
|
US Family Size
|
International Coverage
|
Patent Longevity
|
Forward Citations
|
Abstract
Antibodies having binding affinity for two desired antigens, hereinafter "recombinant monoclonal antibodies"; recombinant monoclonal antibodies produced by a quadroma cell or a trioma cell; and methods for producing recombinant monoclonal antibodies by means of a quadroma cell or a trioma cell, wherein a quadroma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a hybridoma cell which produces an antibody having specific binding affinity for another desired antigen, and wherein a trioma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a lymphocyte which produces an antibody having specific binding affinity to another desired antigen.
First Claim
Related Publications
- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
| Patent Owner | Address | Total Patents |
|---|---|---|
| BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | AUSTIN, TX | 2784 |
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Inventor(s)
| Inventor Name | Address | # of filed Patents | Total Citations |
|---|---|---|---|
| Reading, Christopher L | San Diego, CA | 39 | 527 |
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 4,331,647 Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers | 232 | 1980 | |
| 4,361,544 Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers | 108 | 1980 | |
|
|
|||
| 4,359,457 Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant | 49 | 1980 | |
| 4,356,117 Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells | 8 | 1980 | |
|
|
|||
| 4,350,683 Antibody production from hybrid cell line | 60 | 1980 | |
|
|
|||
| 4,348,376 Tumor localization and therapy with labeled anti-CEA antibody | 100 | 1980 | |
|
|
|||
| 4,376,110 Immunometric assays using monoclonal antibodies | 682 | 1980 | |
|
|
|||
| 4,411,993 Hybridoma antibody which inhibits interleukin 2 activity | 52 | 1981 | |
|
|
|||
| 4,271,145 Process for producing antibodies to hepatitis virus and cell lines therefor | 48 | 1979 | |
|
|
|||
| 4,284,412 Method and apparatus for automated identification and enumeration of specified blood cell subclasses | 137 | 1979 | |
|
|
|||
| 4,361,549 Complement-fixing monoclonal antibody to human T cells, and methods of preparing same | 30 | 1979 | |
|
|
|||
| 4,361,647 Sandwich immunoassay and compositions for use therein | 18 | 1980 | |
|
|
|||
| 4,381,292 Anti-human T-lymphocyte monoclonal antibody | 24 | 1980 | |
|
|
|||
| 4,196,265 Method of producing antibodies | 243 | 1978 | |
|
|
|||
| 4,349,528 Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen | 39 | 1979 | |
Patent Citation Ranking
Forward Cites
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,491,071 Reagents and methods for the detection and quantification of testosterone in fluid samples | 7 | 1993 | |
| 5,518,887 Immunoassays empolying generic anti-hapten antibodies and materials for use therein | 27 | 1993 | |
| 5,476,939 Certain pyridyl and isoquinolyl carbinolamine derivatives | 10 | 1993 | |
| 5,851,781 Reagents and methods for the detection and quantification of testosterone in fluid samples | 4 | 1995 | |
| 5,581,002 Process for the production of 1-.alpha.-(carboxyalkyl)-testosterone | 0 | 1995 | |
| 5,559,210 Reagents and methods for the detection and quantification of testosterone in fluid samples | 0 | 1995 | |
| 5,683,907 Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies | 11 | 1995 | |
| 5,681,960 Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies | 0 | 1995 | |
| 5,670,627 Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies | 11 | 1995 | |
| 5,663,301 Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies | 7 | 1995 | |
| 5,654,160 Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies | 11 | 1995 | |
| 5,631,172 Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies | 8 | 1995 | |
| 5,670,645 Metal ion-ligand coordination complexes, antibodies directed thereto, and assays using such antibodies | 13 | 1995 | |
|
|
|||
| 6,096,289 Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy | 51 | 1998 | |
| 6,254,868 Glycosylated humanized B-cell specific antibodies | 26 | 1998 | |
| 6,387,350 Intraoperative, intravascular and endoscopic tumor and lesion detection, biopsy and therapy | 26 | 1999 | |
| 7,011,812 Targeted combination immunotherapy of cancer and infectious diseases | 11 | 2000 | |
| 7,201,890 Intraoperative, intravascular and endoscopic tumor and lesion detection, biopsy and therapy | 1 | 2002 | |
| 7,300,644 Targeted combination immunotherapy | 4 | 2003 | |
| 7,931,890 Targeted combination immunotherapy of cancer and infectious diseases | 0 | 2005 | |
| 7,514,066 Targeted combination immunotherapy of cancer and infectious diseases | 0 | 2007 | |
|
|
|||
| 5,372,812 Composition and method for acceleration of clot lysis | 8 | 1992 | |
| 5,453,269 Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use | 2 | 1992 | |
| 5,582,862 Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which do not inhibit plasma .alpha.2-antiplasmin | 12 | 1992 | |
| 5,811,265 Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use | 6 | 1993 | |
| 5,609,869 Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use | 2 | 1995 | |
| 5,831,031 Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which do not inhibit plasma .alpha.2-antiplasmin | 1 | 1996 | |
| 6,280,730 Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which do not inhibit plasma .alpha.2-antiplasmin | 1 | 1997 | |
| 6,576,431 Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which do not inhibit plasma .alpha.2-antiplasmin | 0 | 2001 | |
|
|
|||
| 5,567,584 Methods of using biologically active dimerized polypeptide fusions to detect PDGF | 25 | 1994 | |
| 5,843,725 Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions | 53 | 1995 | |
| 5,750,375 Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions | 21 | 1995 | |
| 6,018,026 Biologically active dimerized and multimerized polypeptide fusions | 41 | 1997 | |
| 6,323,323 Ligand-binding, dimerized polypeptide fusions | 65 | 1999 | |
| 6,300,099 Methods for producing secreted ligand-binding fusion proteins | 41 | 2000 | |
| 6,291,212 DNA constructs encoding ligand-binding fusion proteins | 38 | 2000 | |
| 6,291,646 Dimerized polypeptide fusions | 49 | 2000 | |
|
|
|||
| 5,705,614 Methods of producing antigen forks | 2 | 1995 | |
| 5,677,182 Cleavage site blocking antibody to prohormone proteins and uses thereof | 2 | 1995 | |
| 5,702,705 Antibody methods for the treatment of a hormone-mediated disease | 8 | 1995 | |
| 5,686,259 Assay method for the detection of 26kd TNF prohormone | 2 | 1995 | |
| 5,959,084 Bispecific antibodies, methods of production and uses thereof | 6 | 1995 | |
| 6,106,833 Bispecific antibodies, methods of production and use thereof | 4 | 1997 | |
| 6,143,873 Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof | 0 | 1999 | |
|
|
|||
| 6,635,743 Apoptosis inducing molecule II and methods of use | 16 | 2000 | |
| 7,429,646 Antibodies to human tumor necrosis factor receptor-like 2 | 2 | 2000 | |
| 7,597,886 Tumor necrosis factor-gamma | 3 | 2001 | |
| 7,964,190 Methods and compositions for decreasing T-cell activity | 0 | 2003 | |
| 7,820,798 Tumor necrosis factor-gamma | 0 | 2007 | |
| 7,824,675 Use of an antibody that binds human tumor necrosis factor receptor-like 2 | 0 | 2008 | |
| 8,093,363 Tumor necrosis factor-gamma | 0 | 2010 | |
|
|
|||
| 7,718,776 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors | 6 | 2003 | |
| 7,501,552 Transgenic non-human animals for producing chimeric antibodies | 4 | 2004 | |
| 7,910,798 Transgenic animals expressing chimeric antibodies for use in preparing human antibodies | 1 | 2007 | |
| 8,158,419 Transgenic non-human animals for producing chimeric antibodies | 0 | 2008 | |
| 8,367,063 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors | 0 | 2010 | |
| 8,287,856 PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | 0 | 2010 | |
| 8,232,449 Transgenic animals expressing chimeric antibodies for use in preparing human antibodies | 0 | 2011 | |
|
|
|||
| 5,980,896 Antibodies reactive with human carcinomas | 22 | 1993 | |
| 6,020,145 Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 | 5 | 1994 | |
| 5,869,045 Antibody conjugates reactive with human carcinomas | 102 | 1995 | |
| 5,792,456 Mutant BR96 antibodies reactive with human carcinomas | 15 | 1995 | |
| 7,259,002 Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof | 0 | 2004 | |
| 7,482,124 Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema | 0 | 2006 | |
|
|
|||
| 7,973,134 Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways | 0 | 2006 | |
| 7,939,636 Reagents for the detection of protein phosphorylation in c-Src signaling pathways | 0 | 2006 | |
| 7,935,790 Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways | 0 | 2006 | |
| 7,807,789 Reagents for the detection of protein phosphorylation in EGFR-signaling pathways | 0 | 2007 | |
| 7,888,480 Reagents for the detection of protein phosphorylation in leukemia signaling pathways | 0 | 2008 | |
| 7,977,462 Tyrosine phosphorylation sites | 0 | 2008 | |
|
|
|||
| 6,329,507 Dimer and multimer forms of single chain polypeptides | 4 | 1992 | |
| 5,877,291 Multivalent single chain antibodies | 10 | 1994 | |
| 6,071,515 Dimer and multimer forms of single chain polypeptides | 8 | 1995 | |
| 5,892,020 Multivalent single chain antibodies | 16 | 1995 | |
| 6,348,581 High affinity humanized anti-TAG-72 monoclonalantibodies | 6 | 1998 | |
| 7,541,034 Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors | 1 | 1998 | |
|
|
|||
| 5,837,263 Leptospira membrane proteins | 2 | 1995 | |
| 6,140,083 Leptospiral outer membrane protein, LipL46 | 0 | 1998 | |
| 6,261,791 Method for diagnosing cancer using specific PSCA antibodies | 12 | 1999 | |
| 6,262,235 Leptospiral outer membranes protein, LipL46 | 0 | 1999 | |
| 6,699,482 Leptospira rare outer membrane proteins | 2 | 2001 | |
| 7,407,656 PSCA: prostate stem cell antigen and uses thereof | 1 | 2004 | |
|
|
|||
| 5,132,405 Biosynthetic antibody binding sites | 89 | 1988 | |
| 5,091,513 Biosynthetic antibody binding sites | 229 | 1991 | |
| 5,258,498 Polypeptide linkers for production of biosynthetic proteins | 166 | 1992 | |
| 5,482,858 Polypeptide linkers for production of biosynthetic proteins | 37 | 1993 | |
| 5,476,786 Biosynthetic antibody binding sites | 41 | 1993 | |
|
|
|||
| 7,053,210 Efficient synthesis of pyropheophorbide a and its derivatives | 3 | 2003 | |
| 7,501,509 Water soluble tetrapyrollic photosensitizers for photodynamic therapy | 2 | 2006 | |
| 7,897,140 Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents | 0 | 2006 | |
| RE43274 Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy | 0 | 2009 | |
| 7,820,143 Water soluble tetrapyrollic photosensitizers for photodynamic therapy | 1 | 2009 | |
|
|
|||
| 7,084,257 Fully human antibody Fab fragments with human interferon-gamma neutralizing activity | 27 | 2001 | |
| 7,364,736 Antibodies to OPGL | 7 | 2002 | |
| 7,371,381 Anti-galanin antibodies and uses thereof | 0 | 2004 | |
| 7,928,074 Combination therapy with co-stimulatory factors | 0 | 2008 | |
|
|
|||
| 5,670,626 Allergen-specific human IgA monoclonal antibodies for mucosal administration | 13 | 1994 | |
| 5,635,601 Beta-8 integrin subunit antibodies | 3 | 1995 | |
| 7,041,293 HIV env antibodies | 0 | 1998 | |
| 7,258,983 Cardiotrophin-1 compositions and methods for the treatment of tumor | 0 | 2004 | |
|
|
|||
| 7,563,882 Polynucleotides encoding antibodies that bind to the C35 polypeptide | 16 | 2003 | |
| 7,750,125 Antibodies that bind to the C35 polypeptide | 11 | 2007 | |
| 7,968,688 Antibodies that bind to the C35 polypeptide | 0 | 2009 | |
| 7,879,990 Polynucleotides encoding antibodies that bind to the C35 polypeptide | 0 | 2009 | |
|
|
|||
| 8,129,142 Mutations in ion channels | 1 | 2004 | |
| 7,989,182 Nucleic acid encoding SCN1A variant | 0 | 2010 | |
| 8,288,096 Diagnostic method for epilepsy | 0 | 2010 | |
|
|
|||
| 5,503,987 Monoclonal antibodies specific for small moieties and method for their use | 38 | 1992 | |
| 5,639,624 Monoclonal antibodies specific for metallic cations and method therefor | 16 | 1994 | |
| 5,807,695 Metallic cation binding polypeptides and methods therefor | 1 | 1996 | |
|
|
|||
| 5,292,668 Bispecific antibody determinants | 11 | 1990 | |
| 5,523,210 Bispecific antibody determinants | 4 | 1992 | |
| 5,501,854 Hybrid reagents capable of selectively releasing molecules into cells | 4 | 1992 | |
|
|
|||
| 7,563,876 Human monoclonal antibodies to dendritic cells | 0 | 2001 | |
| 7,560,534 Molecular conjugates comprising human monoclonal antibodies to dendritic cells | 0 | 2001 | |
| 8,142,790 Methods of using molecular conjugates comprising monoclonal antibodies to dendritic cells | 0 | 2008 | |
|
|
|||
| 5,858,683 Methods and compositions for the detection of cervical cancer | 10 | 1996 | |
| 6,027,905 Methods for the detection of cervical cancer | 8 | 1997 | |
| 6,803,189 Methods for the detection of cervical cancer | 2 | 1999 | |
|
|
|||
| 7,101,549 Glycoprotein VI and uses thereof | 4 | 2004 | |
| 7,597,888 Glycoprotein VI and uses thereof | 3 | 2006 | |
| 8,137,923 Glycoprotein VI and uses thereof | 0 | 2010 | |
|
|
|||
| 5,134,075 Monoclonal antibody to novel antigen associated with human tumors | 40 | 1989 | |
| 5,411,884 Monoclonal antibody L53 which recognizes a human tumor-associated antigen | 3 | 1993 | |
| 5,491,088 Monoclonal antibody BR 96 and chimeric monoclonal antibodies having the variable region of MAB BR96, which bind to a variant of ley antigen on human carcimona cells | 17 | 1993 | |
|
|
|||
| 5,545,527 Method for testing for mutations in DNA from a patient sample | 43 | 1994 | |
| 5,552,283 Method, reagents and kit for diagnosis and targeted screening for P53 mutations | 25 | 1995 | |
| 6,270,963 Method for testing for mutations in DNA from a patient sample | 5 | 1996 | |
|
|
|||
| 6,306,575 Methods for preparing enriched human hematopoietic cell preparations | 49 | 1995 | |
| 6,117,985 Antibody compositions for preparing enriched cell preparations | 35 | 1998 | |
| 6,482,926 Antibody compositions for preparing enriched cell preparations | 5 | 2000 | |
|
|
|||
| 5,853,988 Diagnosis of retinoblastoma | 1 | 1992 | |
| 7,223,842 Detection of proteins whose absence is associated with a neoplasm | 0 | 1994 | |
| 7,384,735 Retinoblastoma nucleic acids | 0 | 1999 | |
|
|
|||
| 6,111,079 Lead binding polypeptides and nucleotides coding therefore | 5 | 1996 | |
| 5,972,656 Mercury binding polypeptides and nucleotides coding therefore | 2 | 1997 | |
|
|
|||
| 8,236,318 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) | 0 | 2008 | |
| 8,362,214 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) | 0 | 2009 | |
|
|
|||
| 5,770,429 Transgenic non-human animals capable of producing heterologous antibodies | 142 | 1995 | |
| 8,293,480 Transgenic non-human animals for producing chimeric antibodies | 0 | 2008 | |
|
|
|||
| 6,551,592 Bi-and trispecific antibodies for the induction of anti-tumor immunity | 45 | 1997 | |
| 6,514,712 Probe for the early detection of displasias in multilayer tesselated epithelium and for the diagnosis and therapy of carcinomas | 1 | 1998 | |
|
|
|||
| 4,722,892 Monoclonal antibodies against metal chelates | 40 | 1984 | |
| 5,112,951 Separation of anti-metal chelate antibodies | 4 | 1989 | |
|
|
|||
| 6,025,143 Antibodies directed against peptides derived from the SMR1 polypeptide | 6 | 1995 | |
| 6,916,607 PEPTIDES AND POLYPEPTIDES DERIVED FROM THE SUBMAXILLARY GLAND OF THE RAT CORRESPONDING POLYCLONAL AND MONOCLONAL ANTIBODIES CORRESPONDING HYBRIDOMAS AND USES OF THESE PRODUCTS FOR DIAGNOSIS FOR DETECTION OR THERAPEUTIC PURPOSES | 1 | 1999 | |
|
|
|||
| 5,470,956 Antibodies for mevalonic acid and methods for immunological determination of mevalonic acid by using them | 3 | 1994 | |
| 5,591,648 Antibodies for mevalonic acid and methods for immunological determination of mevalonic acid by using them | 2 | 1995 | |
|
|
|||
| 6,063,621 Antibodies to a multidrug resistance protein | 5 | 1995 | |
| 5,882,875 Methods for identifying multidrug resistant tumor cells | 0 | 1995 | |
|
|
|||
| 5,712,370 Erythropoietin (EPO) peptides and antibodies directed against these | 4 | 1994 | |
| 6,932,968 Erythropoietin (EPO) peptides and antibodies directed against these | 0 | 1997 | |
|
|
|||
| 5,141,736 Bispecific monoclonal antibody, its production and use | 16 | 1989 | |
| 5,506,135 Hybrid monoclonal antibodies, their production and use | 0 | 1994 | |
|
|
|||
| 6,740,493 Bone precursor cells: compositions and methods | 4 | 1997 | |
| 7,498,170 Bone precursor cells: compositions and methods | 0 | 2004 | |
|
|
|||
| 5,679,777 Hemoglobins as drug delivery agents | 34 | 1994 | |
| 5,759,517 Hemoglobins as drug delivery agents | 7 | 1995 | |
|
|
|||
| 6,207,805 Prostate cell surface antigen-specific antibodies | 2 | 1998 | |
| 6,512,096 Prostate cell surface antigen-specific antibodies | 3 | 2001 | |
|
|
|||
| 6,899,864 Morpholino imaging and therapy | 2 | 2002 | |
| 7,405,342 Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor | 0 | 2004 | |
|
|
|||
| 7,094,882 Growth factor which acts through erb b-4 rtk | 2 | 2001 | |
| 7,981,997 Growth factor which acts through ErbB-4 RTK | 0 | 2009 | |
|
|
|||
| 5,413,913 Erythrocyte agglutination assay | 3 | 1994 | |
|
|
|||
| 5,583,003 Agglutination assay | 3 | 1994 | |
|
|
|||
| 7,422,899 Antibodies to the human prolactin receptor | 0 | 2006 | |
|
|
|||
| 4,874,693 Method for assessing placental dysfunction | 21 | 1986 | |
|
|
|||
| 4,714,681 Quadroma cells and trioma cells and methods for the production of same | 64 | 1984 | |
|
|
|||
| 5,864,019 Multivalent antigen-binding proteins | 2 | 1995 | |
|
|
|||
| 4,978,745 Immunoreactive heterochain antibodies | 18 | 1987 | |
|
|
|||
| 8,062,635 Bispecific antibody substituting for functional proteins | 0 | 2004 | |
|
|
|||
| 4,649,106 Distinguishing subsets of human cells | 2 | 1984 | |
|
|
|||
| 5,602,234 Stable antibody solution and method for preparing same | 0 | 1995 | |
|
|
|||
| 5,264,341 Selective cloning for high monoclonal antibody secreting hybridomas | 12 | 1989 | |
|
|
|||
| 6,015,680 Human lung adenocarcinoma-related monoclonal antibody and immunoassay method which uses the same | 1 | 1997 | |
|
|
|||
| 4,777,245 Non-human primate monoclonal antibodies and methods | 10 | 1985 | |
|
|
|||
| 7,306,785 Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using | 0 | 2004 | |
|
|
|||
| 7,033,774 Determination of recombinant glycosylated proteins and peptides in biological fluids | 0 | 2003 | |
|
|
|||
| 5,256,395 Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells | 61 | 1987 | |
|
|
|||
| 7,910,108 Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases | 0 | 2007 | |
|
|
|||
| 8,354,104 Monoclonal antibodies for treatment of cancer | 0 | 2008 | |
|
|
|||
| 7,371,383 Recombinant anti-interleukin-9 antibodies | 2 | 2003 | |
|
|
|||
| 5,106,951 Antibody conjugates | 59 | 1989 | |
|
|
|||
| 5,719,030 Monoclonal antibody to prostate-derived acid phosphatase and method for determination of acid phosphatase using the same as well as kit for determination | 2 | 1995 | |
|
|
|||
| 8,221,983 Gene products differentially expressed in cancerous cells | 0 | 2010 | |
|
|
|||
| 5,171,665 Monoclonal antibody to novel antigen associated with human tumors | 57 | 1989 | |
|
|
|||
| 5,242,824 Monoclonal antibody to human carcinomas | 21 | 1989 | |
|
|
|||
| 5,686,071 Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease | 2 | 1995 | |
|
|
|||
| 6,114,506 Composition and method for enhancing fibrinolysis | 0 | 1997 | |
|
|
|||
| 4,831,122 Radioimmunotoxins | 36 | 1986 | |
|
|
|||
| 6,060,285 Process for the production of hetero-bispecific antibodies | 4 | 1990 | |
|
|
|||
| 7,311,906 Anti-viral activity of an anti-thymidine kinase monoclonal antibody | 1 | 2005 | |
|
|
|||
| 6,399,065 Methods for modulating SLAM-expressing T cells | 0 | 1997 | |
|
|
|||
| 5,562,913 Formulation for use in smokers | 16 | 1994 | |
|
|
|||
| 5,728,821 Mutant BR96 antibodies reactive with human carcinomas | 9 | 1994 | |
|
|
|||
| 6,867,189 Use of adipsin/complement factor D in the treatment of metabolic related disorders | 5 | 2002 | |
|
|
|||
| 5,316,932 Homogeneous denatured human 06-guanine alkyltransferase prepared by immunoaffinity chromatography using monoclonal antibody specific for enzyme | 1 | 1993 | |
|
|
|||
| 6,491,918 Antibody compositions for preparing enriched dendritic cell preparations | 7 | 1999 | |
|
|
|||
| 4,578,360 Specific binding assay conjugate with spaced-apart receptors | 11 | 1982 | |
|
|
|||
| 4,634,666 Human-murine hybridoma fusion partner | 51 | 1984 | |
|
|
|||
| 5,252,711 Monoclonal antibodies useful in deodorizing skin and antibody fragments thereof | 2 | 1991 | |
|
|
|||
| 6,245,898 Monoclonal antibodies that recognize antigens associated with tumor metastasis | 9 | 1999 | |
|
|
|||
| 5,466,784 Monoclonal antibodies to salinomycin and method for detecting the same | 0 | 1993 | |
|
|
|||
| 5,496,549 Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis | 3 | 1994 | |
|
|
|||
| 6,258,358 Targeted immunostimulation with bispecific reagents | 3 | 1995 | |
|
|
|||
| 5,716,836 Anti-sulfated tyrosine antibody specific for sulfated tyrosine, process for producing the same, and hybridoma capable of producing anti-sulfated tyrosine monoclonal antibody specific for sulfated tyrosine | 4 | 1994 | |
|
|
|||
| 6,894,021 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation | 12 | 2001 | |
|
|
|||
| 7,090,842 Murine monoclonal anti-idiotype antibody 3H1 sequences for human carcinoembryonic antigen | 1 | 1995 | |
|
|
|||
| 7,807,168 Selection of human TNFα specific antibodies | 0 | 2008 | |
|
|
|||
| 5,736,342 Biosensor for detecting the presence of chosen analytes | 28 | 1995 | |
|
|
|||
| 4,590,071 Human melanoma specific immunotoxins | 46 | 1984 | |
|
|
|||
| 5,776,697 Characterization or determination of the amount of blood cells by means of poultry antibodies | 0 | 1994 | |
| 6,350,571 Methods for detection and evaluation of bladder cancer | 0 | 1999 | |
| 6,558,648 Targeted combination immunotherapy of cancer and infectious diseases | 2000 | ||
| 7,837,998 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody | 0 | 2005 | |
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |